Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Efficacy of aprepitant for preventing chemotherapy-induced nausea and vomiting
June 23rd, 2005
Scientists explored the efficacy of aprepitant (APR) for avoiding chemotherapy-induced nausea and vomiting (CINV) in patients after emetogenic chemotherapy. According to recent research published in the Journal of Clinical Oncology, "This is the first study in which the NK1-receptor antagonist, APR, was evaluated for the prevention of CINV with moderately emetogenic chemotherapy. Eligible breast cancer patients were naive to emetogenic chemotherapy and treated with cyclophosphamide±doxorubicin or epirubicin." "Patients were randomly assigned to either an APR regimen (day 1, APR 125 mg, ondansetron (OND) 8 mg, and dexamethasone 12 mg...
Source: Women's Health Weekly (2005-06-23)
|
